首页> 美国卫生研究院文献>Cancer Biology Therapy >The expression of P2X7 receptors in EPCs and their potential role in the targeting of EPCs to brain gliomas
【2h】

The expression of P2X7 receptors in EPCs and their potential role in the targeting of EPCs to brain gliomas

机译:P2X7受体在EPC中的表达及其在EPC靶向脑胶质瘤中的潜在作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

In order to use endothelial progenitor cells (EPCs) as a therapeutic and imaging probe to overcome antiangiogenic resistance for gliomas, how to enhance proliferation and targeting ability of transplanted EPCs is a high priority. Here, we confirmed, for the first time, the expression of P2X7 receptors in rat spleen-derived EPCs. Activation of P2X7 receptors in EPCs by BzATP promoted cells proliferation and migration, rather than apoptosis. In vivo, the homing of transplanted EPCs after long-term suppression of P2X7 receptors by persistent BBG stimulation was evaluated by MRI, immunohistochemistry and flow cytometry. Compared to the group without BBG treatment, less transplanted EPCs homed to gliomas in the group with BBG treatment, especially integrated into the vessels containing tumor-derived endothelial cells in gliomas. Moreover, western blot showed that CXCL1 expression was downregulated in gliomas with BBG treatment, which meant P2X7 receptors suppression inhibited the homing of EPCs to gliomas through down-regulation of CXCLl expression. Further, effects of P2X7 receptors on C6 glioma cells or gliomas were evaluated at the same dose of BzATP or BBG used in EPCs experiments in vitro and in vivo. MTT assay and MRI revealed that P2X7 receptors exerted no significant promoting effect on C6 glioma cells proliferation, gliomas growth and angiogenesis. Taken together, our findings imply the possibility of promoting proliferation and targeting ability of transplanted EPCs to brain gliomas in vivo through P2X7 receptors, which may provide new perspectives on application of EPCs as a therapeutic and imaging probe to overcome antiangiogenic resistance for gliomas.
机译:为了使用内皮祖细胞(EPC)作为治疗和成像探针来克服对神经胶质瘤的抗血管生成抗性,如何增强移植的EPC的增殖和靶向能力是当务之急。在这里,我们首次证实了大鼠脾源性EPC中P2X7受体的表达。 BzATP激活EPC中的P2X7受体可促进细胞增殖和迁移,而不是凋亡。在体内,通过MRI,免疫组化和流式细胞术评估了持久性BBG刺激长期抑制P2X7受体后移植的EPC的归巢。与未使用BBG治疗的组相比,使用BBG治疗的组中归入神经胶质瘤的移植EPC较少,特别是整合到含有胶质瘤中肿瘤来源的内皮细胞的血管中。此外,蛋白质印迹显示,BBG处理在胶质瘤中CXCL1表达下调,这意味着P2X7受体抑制通过下调CXCL1表达抑制了EPCs向胶质瘤的归巢。此外,在体外和体内在EPC实验中使用相同剂量的BzATP或BBG评估了P2X7受体对C6胶质瘤细胞或神经胶质瘤的作用。 MTT分析和MRI显示P2X7受体对C6神经胶质瘤细胞增殖,神经胶质瘤生长和血管生成没有明显的促进作用。综上所述,我们的发现暗示可能通过P2X7受体在体内促进移植的EPC对脑胶质瘤的增殖和靶向能力,这可能为EPC作为治疗和成像探针克服胶质瘤的抗血管生成抗性提供新的观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号